Table 2.

Neutralizing antibody (NAb) titers in cancer patients receiving immunotherapy at several timepoints after COVID-19 vaccination.

Timepoint	Mean NAb Titers ± Standard Deviation	Median NAb Titers (IQR)
Baseline (D1)	15.8 ± 9.4	14.2 (10.7–20.8)
Prior to 2nd dose (D22)	29.1 ± 24.7	23.4 (13–39.8)
1 month after 2nd dose (D50)	70.7 ± 31.8	87.1 (46.9–95.9)
3 months after 2nd dose (D90)	61.3 ± 28.9	70.2 (35.9–85.7)
6 months after 2nd dose (D180)	48.4 ± 28.2	49.7 (21.1–78.8)
1 month after 3rd dose (3rd + 30D)	96.6 ± 2.1	97.5 (96.5–97.9)

IQR: interquartile range.